Multiple myeloma remains an incurable hematological malignancy despite the availability of several treatments. Resistance to therapy is the primary challenge associated with the disease’s relapse and recurrence, especially in elderly patients. The foremost goal in the third-line treatment of multiple myeloma is extending the patient’s survival. The mainstays of treatment have been agents that affect the immune system, such as Bristol Myers Squibb’s Revlimid and Pomalyst / Imnovid used with the generic corticosteroid dexamethasone. The prescribing of proteasome inhibitors such as Amgen / Ono Pharmaceutical’s Kyprolis and Takeda’s Ninlaro, along with the emergence of novel drugs such as Janssen’s Darzalex, Sanofi’s Sarclisa, and Karyopharm’s Xpovio, is having an impact on treatment choices in the third-line setting. However, in the absence of a uniform treatment regimen, the choice of third-line therapy for multiple myeloma remains fragmented.
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European hematologist-oncologists fielded in May 2021
Key companies: Janssen, Bristol Myers Squibb, Takeda, Amgen / Ono Pharmaceutical, Sanofi, Karyopharm Therapeutics.
Key drugs: Darzalex, Revlimid, Ninlaro, Kyprolis, Pomalyst / Imnovid, Sarclisa, Xpovio